Anlotinib offers convenient oral dosing compared to intravenous infusion for currently available anti-angiogenic inhibitors and has been studied in the first-line setting for NSCLC plus chemotherapy.25 We hypothesized that anlotinib in combination with an EGFR-TKI would be more effective than EGFR-TKI monotherapy for advanced NSCLC in the first-line setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.